United for Health Equity - Living PDX Program (U4HELPP)

United for Health Equity - Living PDX 计划 (U4HELPP)

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT – OVERALL The United for Health Equity-Living PDX Program (U4HELPP) seeks to develop >500 new patient-derived xenograft (PDX) models of cancers originated from the breast, pancreas, colon, liver, lung, and other advanced peritoneal cancers. These PDXs will be made from >60% of patients from underrepresented populations which our safety-net clinical system serves. To develop such a large number and diverse set of PDXs, we have enlisted the support of a set of surgeons that specialize in each cancer type. Once extracted, the tumors are immediately provided to the U4HELPP PDX Core which functions to propagate, distribute, and cryopreserve them. Successfully generated PDXs will be subjected to genomic characterization and quantitative ancestral profiling by the U4HELPP Bioinformatics Core so that we can better understand how ancestry contributes to genetics and responses to targeted therapeutics. The PDXs will be provided to two Research Projects, that will focus on either pancreatic cancer or breast cancer. The Pancreatic Cancer project will generate large-scale proteomics insights from over 200 PDXs to refine subtypes of the disease and identify more effective therapeutics from Black and White patients. The Breast Cancer project will utilize 20 PDXs that are Basal-like breast cancers, characterize their metastatic profiles, define proteogenomic pathways that mediate metastatic growth, and target metastases with synergistic investigational new drug combinations. The information from these PDXs and Projects will be shared with the U4HELPP Pilot Projects and Trans-Network Activities Core which will award Pilot Project grants to utilize the PDXs generated by us and our partnering PDXNet institutions. All of the PDXs and insights gained will be shared with the NCI with the goal of reducing cancer disparities. Through this team effort we are confident that we will be able to develop these unique resources and generate significant preliminary data that will support investigator initiated clinical trials at the Massey Cancer Center.
项目摘要/摘要--总体 美国健康公平-生活PDX计划(U4HELPP)寻求开发>500新患者衍生 异种移植(PDX)肿瘤模型起源于乳癌、胰腺癌、结肠癌、肝癌、肺癌等晚期肿瘤。 腹膜癌。这些PDX将由60%的患者组成,这些患者来自代表人数不足的人群 我们的安全网临床系统服务于。为了开发如此大量和多样化的PDX,我们招募了 一组专门研究每种癌症类型的外科医生的支持。一旦摘除肿瘤,肿瘤就会立即 提供给U4HELPP PDX核心,该核心负责传播、分发和冷冻保存它们。 成功生成的PDX将接受基因组特征和定量祖先特征描述 U4HELPP生物信息学核心,这样我们就可以更好地了解祖先是如何对遗传学做出贡献的 以及对靶向治疗的反应。PDX将被提供给两个研究项目,这两个项目将专注于 要么是胰腺癌,要么是乳腺癌。胰腺癌项目将产生大规模的蛋白质组学 来自200多个PDX的见解,以提炼疾病亚型并从Black确定更有效的治疗方法 还有白人病人。乳腺癌项目将利用20种基底样乳腺癌的PDX, 确定它们的转移特征,确定介导转移生长的蛋白质组途径,并靶向 与协作性研究新药组合的转移。来自这些PDX的信息和 项目将与U4HELPP试点项目和将授予试点的跨网络活动核心共享 项目拨款用于利用我们和我们的合作PDXNet机构生成的PDX。所有的PDX和 所获得的见解将与国家癌症研究所分享,目标是减少癌症差异。通过这个团队的努力 我们相信,我们将能够开发这些独特的资源,并产生重要的初步成果 数据将支持研究人员在梅西癌症中心发起的临床试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joshua (Chuck) Harrell其他文献

Joshua (Chuck) Harrell的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joshua (Chuck) Harrell', 18)}}的其他基金

Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases
研究项目 2 蛋白质基因组引导的乳腺癌患者异种移植转移的治疗靶向
  • 批准号:
    10733315
  • 财政年份:
    2023
  • 资助金额:
    $ 103.1万
  • 项目类别:
Characterization of metastasis models derived from breast cancer patients of African descent
非洲裔乳腺癌患者转移模型的表征
  • 批准号:
    10669268
  • 财政年份:
    2022
  • 资助金额:
    $ 103.1万
  • 项目类别:
Characterization of metastasis models derived from breast cancer patients of African descent
非洲裔乳腺癌患者转移模型的表征
  • 批准号:
    10510244
  • 财政年份:
    2022
  • 资助金额:
    $ 103.1万
  • 项目类别:
Circumventing acquired carboplatin resistance in triple-negative breast cancers
规避三阴性乳腺癌的获得性卡铂耐药性
  • 批准号:
    10159229
  • 财政年份:
    2020
  • 资助金额:
    $ 103.1万
  • 项目类别:
Circumventing acquired carboplatin resistance in triple-negative breast cancers
规避三阴性乳腺癌的获得性卡铂耐药性
  • 批准号:
    10652411
  • 财政年份:
    2020
  • 资助金额:
    $ 103.1万
  • 项目类别:
Circumventing acquired carboplatin resistance in triple-negative breast cancers
规避三阴性乳腺癌的获得性卡铂耐药性
  • 批准号:
    10714928
  • 财政年份:
    2020
  • 资助金额:
    $ 103.1万
  • 项目类别:
Circumventing acquired carboplatin resistance in triple-negative breast cancers
规避三阴性乳腺癌的获得性卡铂耐药性
  • 批准号:
    10441272
  • 财政年份:
    2020
  • 资助金额:
    $ 103.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了